GlaxoSmithKline (GSK) has acquired a Switzerland-based vaccines company, Okairos, for €250m in cash to boost its existing vaccine platform technology expertise and to continue developing the next generation of vaccines. Under the ...
Tags: Glaxosmithkline, Vaccines Business